| 前收盘价格 | 23.78 |
| 收盘价格 | 23.81 |
| 成交量 | 908,815 |
| 平均成交量 (3个月) | 3,333,424 |
| 市值 | 1,490,639,488 |
| 预期市盈率 (P/E Forward) | 27.93 |
| 价格/销量 (P/S) | 85.26 |
| 股市价格/股市净资产 (P/B) | 6.76 |
| 52周波幅 | |
| 利润日期 | 10 Nov 2025 |
| 营业利益率 (TTM) | -2,815.25% |
| 稀释每股收益 (EPS TTM) | -4.38 |
| 季度收入增长率 (YOY) | -81.50% |
| 总债务/股东权益 (D/E MRQ) | 1,522.46% |
| 流动比率 (MRQ) | 11.99 |
| 营业现金流 (OCF TTM) | -166.25 M |
| 杠杆自由现金流 (LFCF TTM) | -122.89 M |
| 资产报酬率 (ROA TTM) | -15.64% |
| 股东权益报酬率 (ROE TTM) | -241.16% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | uniQure N.V. | 看跌 | 看涨 |
AIStockmoo 评分
-0.4
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.38 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 6.09% |
| 机构持股比例 | 91.95% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Sep 2025 | 4,444,444 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 3,988,971 |
| Aberdeen Group Plc | 30 Sep 2025 | 2,939,743 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 70.00 (HC Wainwright & Co., 192.52%) | 购买 |
| 中 | 49.00 (104.76%) | |
| 低 | 33.00 (Mizuho, 37.90%) | 购买 |
| 平均值 | 49.88 (108.44%) | |
| 总计 | 7 购买, 1 保留 | |
| 平均价格@调整类型 | 26.36 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 11 Dec 2025 | 40.00 (67.15%) | 购买 | 19.75 |
| Mizuho | 09 Dec 2025 | 33.00 (37.90%) | 购买 | 20.78 |
| Chardan Capital | 04 Dec 2025 | 53.00 (121.48%) | 购买 | 22.74 |
| 11 Nov 2025 | 53.00 (121.48%) | 购买 | 30.84 | |
| Wells Fargo | 12 Nov 2025 | 60.00 (150.73%) | 购买 | 30.12 |
| 02 Oct 2025 | 80.00 (234.31%) | 购买 | 54.50 | |
| Leerink Partners | 10 Nov 2025 | 60.00 (150.73%) | 购买 | 26.15 |
| Goldman Sachs | 04 Nov 2025 | 38.00 (58.80%) | 保留 | 30.44 |
| HC Wainwright & Co. | 04 Nov 2025 | 70.00 (192.52%) | 购买 | 30.44 |
| 06 Oct 2025 | 110.00 (359.67%) | 购买 | 52.91 | |
| RBC Capital | 04 Nov 2025 | 45.00 (88.05%) | 购买 | 30.44 |
| 显示更多 | ||||
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 04 Dec 2025 | 公告 | uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease |
| 10 Nov 2025 | 公告 | uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update |
| 06 Nov 2025 | 公告 | uniQure to Announce Third Quarter 2025 Financial Results |
| 03 Nov 2025 | 公告 | uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合